Related Experiment Videos
Interleukin-15 stimulates C2 skeletal myoblast differentiation
L S Quinn1, K L Haugk, S E Damon
1Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Tacoma, Washington 98493, USA.
Biochemical and Biophysical Research Communications
|November 5, 1997
Summary
Interleukin-15 (IL-15) promotes skeletal muscle differentiation when insulin-like growth factors (IGFs) are inhibited. This cytokine may play a physiological role in muscle growth under conditions of low IGF availability.
Area of Science:
- Muscle physiology
- Cellular biology
- Endocrinology
Background:
- Interleukin-15 (IL-15) is a cytokine abundant in skeletal muscle, known to promote muscle protein synthesis.
- Previous studies showed IL-15 had no significant effect on skeletal muscle differentiation in C2 myoblasts.
- Autocrine insulin-like growth factors (IGFs) possess potent differentiation-inducing effects in skeletal muscle cells.
Purpose of the Study:
- To investigate if IL-15 can stimulate skeletal muscle differentiation when the influence of autocrine IGFs is suppressed.
- To explore the role of IL-15 in myogenic differentiation under conditions of altered IGF signaling.
Main Methods:
- Created a C2 myoblast subline (C2-pBP4) stably transfected with IGF binding protein-4 (IGFBP-4) to reduce IGF effects.
- Compared differentiation responses in C2-pBP4 cells to control C2-pLXSN cells.
- Assessed the effect of adding IL-15 to C2-pBP4 myoblasts on differentiation.
Main Results:
- Differentiation responses to both autocrine and exogenous IGFs were reduced 3- to 4-fold in C2-pBP4 cells compared to controls.
- Addition of IL-15 to C2-pBP4 myoblasts resulted in a doubling of differentiated muscle cells.
- IL-15 demonstrated a capacity to stimulate myogenic differentiation when IGF signaling was attenuated.
Conclusions:
- IL-15 can stimulate skeletal muscle differentiation, particularly when the potent effects of IGFs are inhibited.
- The differentiative activity of IL-15 may be physiologically relevant in scenarios with low IGF levels or increased IGF binding proteins.